SEC 13F Intelligence

Managers / Q3 2020 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$2.9B
Q3 2020
Positions
75
Filings on Record
27
2019–present window
Filed
Nov 17, 2020
amendment (RESTATEMENT)

Summary

Boxer Capital, LLC reported $2.9B in U.S.-listed holdings across 75 positions for Q3 2020.

Its largest position, IMMU, represents 13.2% of the portfolio.

Compared with Q2 2020, the fund opened 17 new positions and exited 7.

Portfolio Metrics

Turnover
+16.0%
vs prior filed quarter
Top-10 Concentration
+55.7%
share of reported value
Largest Position
+13.2%
Immunomedics
New / Exited
17 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 76.3%ADR: 12.9%Other: 10.2%ETP: 0.5%
  • Common Stock · 76.3% · $2.2B
  • ADR · 12.9% · $375M
  • Other · 10.2% · $296M
  • ETP · 0.5% · $15M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
2662247DITEOS THERAPEUTICS INCNEW+4.35M4.35M+$107M$107M
PMVPPMV PHARMACEUTICALS INCNEW+2.27M2.27M+$81M$81M
RLAYRELAY THERAPEUTICS INCNEW+1.25M1.25M+$53M$53M
NRIXNURIX THERAPEUTICS INCNEW+1.35M1.35M+$47M$47M
MARINUS PHARMACEUTICALS INCNEW+2.40M2.40M+$31M$31M
PANDPANDION THERAPEUTICS INCNEW+2.11M2.11M+$24M$24M
THERAPEUTICS ACQUISITION CORNEW+1.50M1.50M+$22M$22M
DIREXION SHS ETF TRNEW+250.0K250.0K+$15M$15M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2020

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1IMMUIMMUNOMEDICS INChistory →COM13.22%$383M4.50M
2ONCBEIGENE LTDhistory →SPONSORED ADR11.03%$319M1.11M
3MRTXEURMIRATI THERAPEUTICS INChistory →COM10.13%$293M1.77M
4RVMDREVOLUTION MEDICINES INChistory →COM3.98%$115M3.31M
52662247DITEOS THERAPEUTICS INChistory →COM3.70%$107M4.35M
6SWTXUSDSPRINGWORKS THERAPEUTICS INChistory →COM3.42%$99M2.08M
7PMVPPMV PHARMACEUTICALS INChistory →COM2.78%$81M2.27M
8SGENUSDSEATTLE GENETICS INChistory →COM2.71%$78M400.0K
9ODONATE THERAPEUTICS INCCOM2.42%$70M5.21M
10SG7SAGE THERAPEUTICS INChistory →COM2.31%$67M1.09M
11BDTXBLACK DIAMOND THERAPEUTICS Ihistory →COM2.10%$61M2.01M
12ALLKGUSDALLAKOS INChistory →COM1.90%$55M675.0K
13RLAYRELAY THERAPEUTICS INChistory →COM1.84%$53M1.25M
14ICPTUSDINTERCEPT PHARMACEUTICALS INhistory →COM1.68%$49M1.18M
15NRIXNURIX THERAPEUTICS INChistory →COM1.63%$47M1.35M
16ARGXARGENX SEhistory →SPONSORED ADR1.55%$45M170.9K
17COMPUGEN LTDORD1.34%$39M2.38M
18ESPRESPERION THERAPEUTICS INC NEhistory →COM1.25%$36M975.0K
19RCUSARCUS BIOSCIENCES INChistory →COM1.23%$36M2.08M
20SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.17%$34M2.29M
21RCKTROCKET PHARMACEUTICALS INChistory →COM1.16%$34M1.47M
22AM6AMICUS THERAPEUTICS INChistory →COM1.13%$33M2.33M
23KURAKURA ONCOLOGY INChistory →COM1.11%$32M1.05M
24GOSSGOSSAMER BIO INChistory →COM1.10%$32M2.56M
25RNAGBPAVIDITY BIOSCIENCES INChistory →COM1.09%$32M1.12M
26MARINUS PHARMACEUTICALS INCCOM NEW1.07%$31M2.40M
27ATRECA INCCL A COM1.06%$31M2.20M
28AMARIN CORP PLCSPONS ADR NEW1.02%$29M7.00M
29CYMABAY THERAPEUTICS INCCOM1.00%$29M4.00M
30UNIQURE NVSHS0.97%$28M765.4K
31IDYAIDEAYA BIOSCIENCES INChistory →COM0.96%$28M2.20M
32AKROAKERO THERAPEUTICS INChistory →COM0.88%$26M831.5K
33PASSAGE BIO INCCOM0.87%$25M1.93M
34KDMNKADMON HLDGS INChistory →COM0.84%$24M6.21M
35PANDPANDION THERAPEUTICS INChistory →COM0.83%$24M2.11M
36THERAPEUTICS ACQUISITION CORCOM CL A0.75%$22M1.50M
37ANABANAPTYSBIO INChistory →COM0.66%$19M1.30M
38BMRNBIOMARIN PHARMACEUTICAL INChistory →COM0.66%$19M250.0K
39NEOLEUKIN THERAPEUTICS INCCOM0.62%$18M1.50M
40CABACABALETTA BIO INChistory →COM0.59%$17M1.57M
41KODKODIAK SCIENCES INChistory →COM0.56%$16M275.1K
42AGENEURAGENUS INChistory →COM NEW0.55%$16M4.00M
43ACADACADIA PHARMACEUTICALS INChistory →COM0.53%$15M370.0K
44DIREXION SHS ETF TRDAILY S&P BIOTEC0.52%$15M250.0K
45TCE2CELLDEX THERAPEUTICS INC NEWhistory →COM NEW0.51%$15M1.00M
46GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory →COM0.48%$14M250.0K
47SPPIUSDSPECTRUM PHARMACEUTICALS INChistory →COM0.47%$14M3.33M
48DBV TECHNOLOGIES S ASPONSORED ADR0.45%$13M7.53M
49MISTMILESTONE PHARMACEUTICALS INhistory →COM0.45%$13M1.78M
50PREVAIL THERAPEUTICS INCCOM0.40%$11M1.12M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.